Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ehrlich

Showing results (241-250 of 278) with videos related to

Pageof 28
Sort By:
Vaccine|May 4, 2010
Comparison of immunogenicity and safety between two paediatric TBE vaccinesEva Maria Pöllabauer, Borislava G Pavlova, Alexandra Löw-Baselli, et al.
Plos One|February 2, 2011
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunityAnnett Hessel, Michael Schwendinger, Georg W Holzer, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2022
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extensionSeverine Vermeire, Bruce E Sands, Herbert Tilg, et al.
Vaccine|August 1, 2012
A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memoryAlexandra Loew-Baselli, Borislava G Pavlova, Sandor Fritsch, et al.
Vaccine|August 14, 2012
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose primingMaikel V W van der Velden, Gerald Aichinger, Eva Maria Pöllabauer, et al.
Vaccine|April 6, 2012
Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccineHartmut J Ehrlich, Markus Müller, Herwig Kollaritsch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 2, 2014
Lost opportunities to reduce periconception HIV transmission: safer conception counseling by South African providers addresses perinatal but not sexual HIV transmissionLynn T Matthews, Cecilia Milford, Angela Kaida, et al.
Journal of Clinical Immunology|May 18, 2006
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiencyJoseph A Church, Heinz Leibl, Mark R Stein, et al.
Acta Psychiatrica Scandinavica|January 16, 2023
Childhood trauma and depressive symptoms in bipolar disorder: A network analysisAnna L Wrobel, Sue M Cotton, Anuradhi Jayasinghe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 31, 2019
Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's diseaseJohn D Heiss, Codrin Lungu, Dima A Hammoud, et al.
Pageof 28

Showing results (241-250 of 278) with videos related to

Sort By:
Pageof 28
Vaccine|May 4, 2010
Comparison of immunogenicity and safety between two paediatric TBE vaccinesEva Maria Pöllabauer, Borislava G Pavlova, Alexandra Löw-Baselli, et al.
Plos One|February 2, 2011
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunityAnnett Hessel, Michael Schwendinger, Georg W Holzer, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2022
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extensionSeverine Vermeire, Bruce E Sands, Herbert Tilg, et al.
Vaccine|August 1, 2012
A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memoryAlexandra Loew-Baselli, Borislava G Pavlova, Sandor Fritsch, et al.
Vaccine|August 14, 2012
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose primingMaikel V W van der Velden, Gerald Aichinger, Eva Maria Pöllabauer, et al.
Vaccine|April 6, 2012
Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccineHartmut J Ehrlich, Markus Müller, Herwig Kollaritsch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 2, 2014
Lost opportunities to reduce periconception HIV transmission: safer conception counseling by South African providers addresses perinatal but not sexual HIV transmissionLynn T Matthews, Cecilia Milford, Angela Kaida, et al.
Journal of Clinical Immunology|May 18, 2006
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiencyJoseph A Church, Heinz Leibl, Mark R Stein, et al.
Acta Psychiatrica Scandinavica|January 16, 2023
Childhood trauma and depressive symptoms in bipolar disorder: A network analysisAnna L Wrobel, Sue M Cotton, Anuradhi Jayasinghe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 31, 2019
Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's diseaseJohn D Heiss, Codrin Lungu, Dima A Hammoud, et al.
Pageof 28